High-fat versus high-carbohydrate enteral formulae: effect on blood glucose, C-Peptide, and ketones in patients with type 2 diabetes treated with insulin or sulfonylurea

Nutrition ◽  
1998 ◽  
Vol 14 (11-12) ◽  
pp. 840-845 ◽  
Author(s):  
Alejandro Sanz-París ◽  
Luisa Calvo ◽  
Ana Guallard ◽  
Isabel Salazar ◽  
Ramón Albero
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
High Fat ◽  
C Peptide ◽  
High Carbohydrate

scholarly journals Following a Low Carbohydrate, High Fat Diet Compared to Reduced Calorie, High Carbohydrate Diet as a Nutritional Intervention in Type Two Diabetes Mellitus Patients: A Systematic Review

2020 ◽  
Vol 9 (1) ◽  
pp. 1
Author(s):  
Joy Lewis ◽  
Kevin Haubrick
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Blood Glucose ◽  
High Fat Diet ◽  
High Fat ◽  
Carbohydrate Diet ◽  
Eating Pattern ◽  
High Carbohydrate ◽  
Low Carbohydrate

There is evidence supporting individuals with type 2 diabetes benefit from lifestyle changes through a nutrition intervention that improves diabetic (blood glucose and HgbA1c) and cardiovascular (total cholesterol, HDL, LDL, and triglycerides) biomarkers. The objective of this systematic review was to evaluate if patients with type 2 diabetes following a low carbohydrate, high fat eating pattern is more effective than following a reduced caloric, high carbohydrate eating pattern in the improvement of diabetic (blood glucose and HgbA1c) and cardiovascular (total cholesterol, HDL, LDL, and triglycerides) biomarkers. A literature search was conducted on peer-reviewed research trials registered in PubMed, from January 2007 to September 2019 using combinations of the search terms: Diabetes Mellitus, Type 2 AND Diet, Ketogenic; OR Diet, Carbohydrate-Restricted. The literature was analyzed in chronological order; grouping in four year increments from 2007 to 2019. The thirty-six articles reviewed provide evidence to support the use of a low carbohydrate diet in patients with type 2 diabetes versus a reduced caloric diet. This systematic review highlighted diabetic (HgbA1c and fasting blood glucose) and cardiovascular biomarkers (HDL) of type 2 diabetic patients improve significantly when following a low-carbohydrate, high fat diet versus a reduced calorie, high carbohydrate intake.

723-P: Effect of Low-Carbohydrate High-Fat vs. High-Carbohydrate Low-Fat Diet on HbA1c Control in Chinese Patients with Type 2 Diabetes

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 723-P
Author(s):  
LINGWANG AN ◽  
DANDAN WANG ◽  
XIAORONG SHI ◽  
CHENHUI LIU ◽  
KUEICHUN YEH ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Chinese Patients ◽  
High Fat ◽  
Low Fat ◽  
High Carbohydrate ◽  
Low Fat Diet ◽  
Low Carbohydrate ◽  
Hba1c Control

Abstract 015: Increased 20-HETE Levels Contribute to Impaired Glucose Metabolism and Type 2 Diabetes in Cyp4a14 Knockout Mice Fed on High Fat Diet.

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Varunkumar G Pandey ◽  
Lars Bellner ◽  
Victor Garcia ◽  
Joseph Schragenheim ◽  
Andrew Cohen ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Weight Gain ◽  
Blood Glucose ◽  
High Fat Diet ◽  
Plasma Insulin ◽  
High Fat ◽  
Plasma Insulin Levels

20-HETE (20-Hydroxyeicosatetraenoic acid) is a cytochrome P450 ω-hydroxylase metabolite of arachidonic acid that promotes endothelial dysfunction, microvascular remodeling and hypertension. Previous studies have shown that urinary 20-HETE levels correlate with BMI and plasma insulin levels. However, there is no direct evidence for the role of 20-HETE in the regulation of glucose metabolism, obesity and type 2 diabetes mellitus. In this study we examined the effect of 20-SOLA (2,5,8,11,14,17-hexaoxanonadecan-19-yl-20-hydroxyeicosa-6(Z),15(Z)-dienoate), a water-soluble 20-HETE antagonist, on blood pressure, weight gain and blood glucose in Cyp4a14 knockout (Cyp4a14-/-) mice fed high-fat diet (HFD). The Cyp4a14-/- male mice exhibit high vascular 20-HETE levels and display 20-HETE-dependent hypertension. There was no difference in weight gain and fasting blood glucose between Cyp4a14-/- and wild type (WT) on regular chow. When subjected to HFD for 15 weeks, a significant increase in weight was observed in Cyp4a14-/- as compared to WT mice (56.5±3.45 vs. 30.2±0.7g, p<0.05). Administration of 20-SOLA (10mg/kg/day in drinking water) significantly attenuated the weight gain (28.7±1.47g, p<0.05) and normalized blood pressure in Cyp4a14-/- mice on HFD (116±0.3 vs. 172.7±4.6mmHg, p<0.05). HFD fed Cyp4a14-/- mice exhibited hyperglycemia as opposed to normal glucose levels in WT on a HFD (154±1.9 vs. 96.3±3.0 mg/dL, p<0.05). 20-SOLA prevented the HFD-induced hyperglycemia in Cyp4a14-/- mice (91±8mg/dL, p<0.05). Plasma insulin levels were markedly high in Cyp4a14-/- mice vs. WT on HFD (2.66±0.7 vs. 0.58±0.18ng/mL, p<0.05); corrected by the treatment with 20-SOLA (0.69±0.09 ng/mL, p<0.05). Importantly, glucose and insulin tolerance tests showed impaired glucose homeostasis and insulin resistance in Cyp4a14-/- mice on HFD; ameliorated by treatment with 20-SOLA. This novel finding that blockade of 20-HETE actions by 20-SOLA prevents HFD-induced obesity and restores glucose homeostasis in Cyp4a14-/- mice suggests that 20-HETE contributes to obesity, hyperglycemia and insulin resistance in HFD induced metabolic disorder. The molecular mechanisms underlying 20-HETE mediated metabolic dysfunction are being currently explored.

scholarly journals Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes

2009 ◽  
Vol 94 (1) ◽  
pp. 81-88 ◽  
Author(s):  
David A. D'Alessio ◽  
Amanda M. Denney ◽  
Linda M. Hermiller ◽  
Ronald L. Prigeon ◽  
Julie M. Martin ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Cell Function ◽  
Glycosylated Hemoglobin ◽  
Fasting Blood Glucose ◽  
Dipeptidyl Peptidase ◽  
Islet Function ◽  
C Peptide ◽  
Dipeptidyl Peptidase 4

Abstract Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of action, DPP-4 inhibitors improve glucose tolerance after meals by increasing insulin and reducing glucagon levels in the plasma. However, DPP-4 inhibitors also reduce fasting blood glucose, an unexpected effect because circulating levels of active GIP and GLP-1 are low in the postabsorptive state. Objective: The objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function. Design: We conducted a randomized, double-blind, placebo-controlled trial. Setting: The study was performed in General Clinical Research Centers at two University Hospitals. Subjects: Forty-one subjects with T2DM were treated with metformin or diet, having good glycemic control with glycosylated hemoglobin values of 6.2–7.5%. Intervention: Subjects were treated with vildagliptin (50 mg twice daily) or placebo for 3 months, followed by a 2-wk washout. Major Outcome Measure: We measured insulin secretion in response to iv glucose and arginine before and after treatment and after drug washout. Results: There were small and comparable reductions in glycosylated hemoglobin in both groups over 3 months. Vildagliptin increased fasting GLP-1 levels in subjects taking metformin, but not those managed with diet, and raised active GIP levels slightly. DPP-4 inhibitor treatment improved the acute insulin and C-peptide responses to glucose (50 and 100% respectively; P &lt; 0.05) and increased the slope of the C-peptide response to glucose (33%; P = 0.023). Conclusion: Vildagliptin improves islet function in T2DM under fasting conditions. This suggests that DPP-4 inhibition has metabolic benefits in addition to enhancing meal-induced GLP-1 and GIP activity.

scholarly journals TCM Formula Xiaoyaosan Decoction Improves Depressive-Like Behaviors in Rats with Type 2 Diabetes

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Na Li ◽  
Qun Liu ◽  
Xiao-Juan Li ◽  
Xiao-Hui Bai ◽  
Yue-Yun Liu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
High Fat Diet ◽  
Hippocampal Formation ◽  
Morphological Changes ◽  
Fasting Blood Glucose ◽  
The Body ◽  
High Fat ◽  
Body Weights

The mechanism of depression with type 2 diabetes remains elusive, requiring further study.Objective. To evaluate the effect of TCM formula Xiaoyaosan on depressive-like behaviors in rats with type 2 diabetes.Methods. Rats were divided into 5 groups and drugs were administered during the model period of 21 days. The model of depressive-like behaviors in rats with type 2 diabetes was induced by a high fat diet, low doses of STZ injection, and chronic restraint stress for 21 days. The body weight, fasting blood glucose, ITT, OGTT, 5-HT, DA, depression behaviors, and morphological changes of formation were measured and observed.Results. After modeling, marked changes were found in model rats; behavioral analyses of rats indicated that this modeling method negatively impacts locomotor function. In the H&E staining, changes were found predominately in the CA1 and DG subregions of the hippocampus. After 21 days of treatment by fluoxetine and Xiaoyaosan, rats’ body weights, behaviors and fasting blood glucose, and hippocampal formation were modified.Conclusions. A new model of depressive-like behaviors in rats with type 2 diabetes was successfully created. Xiaoyaosan and fluoxetine in this study independently contribute to exacerbate the disease progression.

scholarly journals Antioxidant Total and HOMA-IR of Diabetic Rats Given Crocatum piper and Andrographis paniculata Leaf Extracts

2021 ◽  
Vol 7 (2) ◽  
pp. 56-61
Author(s):  
Nesti Rahmawati ◽  
Kusmiyati DK ◽  
Diana Nur Afifah
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Wilcoxon Test ◽  
Male Rats ◽  
Assay Method ◽  
High Fat ◽  
Leaf Extracts

Background: Type-2 diabetes mellitus (T2DM) is a silent killer which the prevalence continues to increase in every year. Increased oxidative stress occurs in T2DM. Red betel and bitter herb leaf extracts (RBBH) contain a lot of antioxidants. This combination is expected to provide better safety than if used singly because the content of andrographolid in bitter herb has effect such as nausea, vomiting, loss of appetite, and antifertility if consumed in high doses.Objective: The study aimed to prove the effect of red betel and bitter herb leaf extracts on antioxidant total and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) in T2DM rats given high-fat diet and Streptozotocin (STZ) induction.Methods: Experimental randomized study with pre-post-test control group design using 25 Sprague Dawley male rats. T2DM model was conducted by providing high-fat feed for 14 days and induction of Streptozotocin-Nicotinamide, then given a combination of red betel and bitter herb leaf extracts at doses of 237.5 mg/kg BW, 225 mg/kg BW, and 212.5 mg/kg BW for 21 days. The measurement of antioxidant total used 2,2-azino-bis-3-ethylbenzthiazoline-6-sulphonic acid (ABTS) method. HOMA-IR measured by ELISA (Enzyme-linked immunosorbent assay) method using insulin level equation and fasting blood glucose level measured by glucose oxidase-peroxidase aminoantrypirin (GOD-PAP). Data analysis used paired t-test, wilcoxon test, and ANOVA test to analyze differences in antioxidant total and HOMA-IR value among groups and followed by Bonferroni post-hoc test.Results: All treatments could reduce HOMA-IR and significantly increase antioxidant total (p<0.05). The most decrease in HOMA-IR and increase in antioxidant total at dose 237.5 mg/kg BW of red betel and bitter herb leaf extracts.Conclusion: The combination of red betel and bitter herb leaf extracts with dose 237.5 mg/kg BW, 225 mg/kg BW, and 212.5 mg/kg BW can improve blood glucose, insulin, and HOMA-IR levels in type-2 diabetes mellitus rats. 

scholarly journals Experience of the use of liraglutide (Victoza) in women with type 2 diabetes mellitus and obesity

2011 ◽  
Vol 14 (2) ◽  
pp. 91-93
Author(s):  
Vladimir Ivanovich Kudinov ◽  
Natalya Vladimirovna Zolotareva ◽  
Maria Sergeeva Nichitenko
Keyword(s):  
Type 2 Diabetes ◽  
Blood Glucose ◽  
Total Duration ◽  
Hdl Cholesterol ◽  
The Body ◽  
C Peptide ◽  
Target Values ◽  
Before And After ◽  
Total Fat

Aim. To study efficacy of treatment with liraglutide in women with type 2 diabetes (T2D) and obesity. Materials and methods. A group of 12 women aged 52-58 yr with T2D duration of 3-5 years, BMI 32-35 kg/m2, abnormally high C-peptide level,and НbА1с 7.5-8.5% were treated with 1500-2000 mg metformin/day and sulfonylureas at 50% of the maximum dose. Liraglutide was given insteadof sulfonylureas by a standard method (0.6 U/day for 1 week subcutaneously and 1.2 U/day thereafter). The total duration of therapy was 3 months.We analysed blood glucose level before and 2 hr after meals, НbА1с, lipidogram, C-peptide, HOMA index, BMI, waist circumference, percent of totalfat in the body, frequency of hypoglycemia, and side effects (nausea). Results. All patients achieved target values of НbА1с and a significant decrease in blood glucose before and after meals, body weight, total fat content,BMI, HOMA, systolic blood pressure; HDL cholesterol increased while LDL decreased. No case of hypoglycemia was documented. All the patientshad mild nausea of short duration (2-3 days). Conclusion. The use of liraglutide (Victoza) in women with T2D and obesity improve carbohydrate metabolism and insulin resistance without seriousside effects.

Sign in / Sign up

Export Citation Format

Share Document